Reported about 1 year ago
Chang Gung Intelligent announced on June 11, 2024, that its product, the 'Bone Age Diagnostic System,' has received FDA medical device approval, making it the 35th medical device approval for the company globally, including 11 from the FDA, 14 from TFDA in Taiwan, four from Thailand, four from Vietnam, one from Singapore, and one from Malaysia. The system eliminates the need for traditional clinical physicians to search for charts and can quickly provide bone age analysis results and recommendations. Chang Gung has achieved record-high revenue exceeding the previous year, with a 433% year-on-year increase in the first five months. They are optimistic about the possibility of turning a profit for the full year. The company is also collaborating with Singapore-based kidney disease medical company AWAK to develop an AI model for kidney disease progression prediction, currently undergoing testing and clinical preparation at Mayo Clinic. This collaboration aims to enhance the accuracy and reliability of the AI model with solid clinical data support.
Source: YAHOO